Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

@article{Blauvelt2017LongtermMO,
  title={Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial},
  author={Andrew Blauvelt and Marjolein S. de Bruin-Weller and Melinda J Gooderham and Jennifer Clay Cather and Brad Shumel},
  journal={The Lancet},
  year={2017},
  volume={389},
  pages={2287-2303}
}
BACKGROUND Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis. Previous 16-week monotherapy studies showed that dupilumab substantially improved signs and symptoms of moderate-to-severe atopic dermatitis with acceptable safety, validating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pathogenesis… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 78 CITATIONS, ESTIMATED 37% COVERAGE

Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis

VIEW 20 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis

  • American Journal of Clinical Dermatology
  • 2017
VIEW 23 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis

  • American Journal of Clinical Dermatology
  • 2018
VIEW 7 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Dupilumab: A review of its use in the treatment of atopic dermatitis.

  • Journal of the American Academy of Dermatology
  • 2018
VIEW 9 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED

Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials.

  • Journal of the American Academy of Dermatology
  • 2018
VIEW 7 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED

Dupilumab: A New Paradigm for the Treatment of Allergic Diseases.

  • Journal of investigational allergology & clinical immunology
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials.

  • Journal of the American Association of Nurse Practitioners
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Dupilumab: First Global Approval

  • Drugs
  • 2017
VIEW 15 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2017
2019

CITATION STATISTICS

  • 9 Highly Influenced Citations

  • Averaged 26 Citations per year from 2017 through 2019

Similar Papers

Loading similar papers…